View Older Stories View More Recent Stories
-
Guardant Health (GH) adds full suite of IHC testing
-
Guardant Health (GH) Introduces Hereditary Cancer Testing to Identify Inherited Predispositions to Certain Types of Cancer
-
Guardant Health (GH) PT Raised to $57 at Scotiabank
-
Guardant Health (GH) PT Raised to $65 at Canaccord Genuity
-
Guardant Health (GH) Tops Q1 EPS by 26c, Updates Guidance
-
Guardant Health (GH) Presents Data Demonstrating Strong Performance of Shield Multi-Cancer Detection Test Across 10 Tumor Types
-
Guardant Health (GH) Launches Guardant360 Tissue, First Tissue Molecular Profiling Test with Comprehensive Multiomic Analysis to Provide a More Complete View of Cancer
-
Guardant Health (GH) Announces Strategic Collaboration With Pfizer to Support Development and Commercialization of New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform
-
Mizuho Starts Guardant Health (GH) at Outperform
-
Guardant Health (GH) partners with Bayshore HealthCare to offer testing portfolio in Canada
-
Guardant Health's (GH) Shield Blood Test Now Covered for VA Community Care Beneficiaries
-
Positive estimate revisions should drive this stock higher still - analyst
-
TD Cowen Reiterates Buy Rating on Guardant Health (GH)
-
Citi Reiterates Buy Rating on Guardant Health (GH)
-
Raymond James Reiterates Outperform Rating on Guardant Health (GH)
-
Guardant Health (GH) Receives ADLT Status From CMS for Shield Blood Test
-
TD Cowen: 'Top 10 Themes Coming Out of 45th Annual Health Care Conference'
-
Guardant Health (GH) PT Raised to $52 at Morgan Stanley
-
Guardant Health (GH) PT Raised to $60 at Canaccord Genuity
-
Guardant Health (GH) PT Raised to $60 at Canaccord Genuity
-
Guardant Health (GH) PT Raised to $60 at BTIG
-
Guardant Health (GH) PT Raised to $60; Bernstein: 'We Remain Bullish on the Stock'
-
Guardant Health (GH) PT Raised to $60 at Citi
-
Guardant Health (GH) PT Raised to $56 at BofA Securities
-
Guardant Health (GH) Tops Q4 EPS by 16c; offers guidance
-
Bernstein SocGen Group Reiterates Outperform Rating on Guardant Health (GH)
-
Guardant Health (GH) 1.74M Share Block Trades
-
Guardant Health (GH) Announces Debt Exchange Transactions
-
Guardant Health (GH) to Present Data at ASCO GI Demonstrating the Value of Its Precision Oncology Tools
-
Barclays Starts Guardant Health (GH) at Overweight
-
Increasing unusual put option volume: TAL XP CHD MLCO EXC PCG GH RGTI WMB ICE TEM IYR
-
Raymond James Reiterates Outperform Rating on Guardant Health (GH)
-
Raymond James Reiterates Outperform Rating on Guardant Health (GH)
-
TD Cowen Reiterates Buy Rating on Guardant Health (GH)
-
Guardant Health (GH) PT Raised to $55 at BTIG
-
Canaccord Genuity Reiterates Buy Rating on Guardant Health (GH)
-
Guardant Health (GH) and ConcertAI Collaborate to Form First Data-As-A-Service That Integrates Clinical and Tumor Profiling Data to Accelerate Cancer Therapy Research and Development
-
Guardant Health (GH) named top pick at UBS
-
Jefferies Reiterates Buy Rating on Guardant Health (GH)
-
Piper Sandler Reiterates Overweight Rating on Guardant Health (GH) After a 'Positive' Survey
-
Guardant Health (GH) Announces Collaboration With Boehringer Ingelheim to Develop Companion Diagnostic for Detection of Specific Mutations in Advanced Lung Cancer
-
Is Trump 2.0 good or bad for healthcare stocks?
-
Guardant Health (GH) PT Raised to $60 at Leerink Partners
-
Guardant Health (GH) Tops Q3 EPS by 29c ; Offers Guidance
-
Guardant Health (GH) Appoints Roberto A. Mignone to its Board
-
Guardant Health (GH) Weakness Said to be Tied to Data From Exact Sciences (EXAS)
-
Midday movers: PDD Holdings, NVIDIA fall; Xpeng gains
-
Guardant Health (GH) enters Open Market Sale Agreement with Jefferies
-
Guardant Health (GH) PT Raised to $42 at TD Cowen
-
Guardant Health (GH) PT Raised to $40 at Jefferies
